Unicycive Therapeutics UNCY Stock
Unicycive Therapeutics Price Chart
Unicycive Therapeutics UNCY Financial and Trading Overview
| Unicycive Therapeutics stock price | 7.2 USD |
| Previous Close | 7.38 USD |
| Open | 7.46 USD |
| Bid | 5.74 USD x 200 |
| Ask | 9.6 USD x 200 |
| Day's Range | 7.41 - 8.01 USD |
| 52 Week Range | 3.71 - 11 USD |
| Volume | 934.78K USD |
| Avg. Volume | 562K USD |
| Market Cap | 202.92M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.25 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41 USD |
UNCY Valuation Measures
| Enterprise Value | 149.15M USD |
| Trailing P/E | N/A |
| Forward P/E | 1.1577795 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.0870147 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.983 |
Trading Information
Unicycive Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 11.48% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 11 USD |
| 52 Week Low | 3.71 USD |
| 50-Day Moving Average | 7.28 USD |
| 200-Day Moving Average | 5.94 USD |
UNCY Share Statistics
| Avg. Volume (3 month) | 562K USD |
| Avg. Daily Volume (10-Days) | 766.13K USD |
| Shares Outstanding | 26.7M |
| Float | 24.28M |
| Short Ratio | 3.71 |
| % Held by Insiders | 2.35% |
| % Held by Institutions | 37.64% |
| Shares Short | 2.03M |
| Short % of Float | 7.78% |
| Short % of Shares Outstanding | 7.59% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -40.55% |
| Return on Equity (ttm) | -163.13% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -29931000 USD |
| Net Income Avi to Common (ttm) | -39948000 USD |
| Diluted EPS (ttm) | -2.25 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 54.59M USD |
| Total Cash Per Share (mrq) | 2.04 USD |
| Total Debt (mrq) | 815K USD |
| Total Debt/Equity (mrq) | 2.16 USD |
| Current Ratio (mrq) | 2.399 |
| Book Value Per Share (mrq) | 1.494 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -28655000 USD |
| Levered Free Cash Flow (ttm) | -7113125 USD |
Profile of Unicycive Therapeutics
| Country | United States |
| State | CA |
| City | Mountain View |
| Address | 1975 West El Camino Real |
| ZIP | 94040 |
| Phone | 650 351 4495 |
| Website | https://unicycive.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 21 |
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Q&A For Unicycive Therapeutics Stock
What is a current UNCY stock price?
Unicycive Therapeutics UNCY stock price today per share is 7.2 USD.
How to purchase Unicycive Therapeutics stock?
You can buy UNCY shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Unicycive Therapeutics?
The stock symbol or ticker of Unicycive Therapeutics is UNCY.
Which industry does the Unicycive Therapeutics company belong to?
The Unicycive Therapeutics industry is Biotechnology.
How many shares does Unicycive Therapeutics have in circulation?
The max supply of Unicycive Therapeutics shares is 26.7M.
What is Unicycive Therapeutics Price to Earnings Ratio (PE Ratio)?
Unicycive Therapeutics PE Ratio is now.
What was Unicycive Therapeutics earnings per share over the trailing 12 months (TTM)?
Unicycive Therapeutics EPS is -2.25 USD over the trailing 12 months.
Which sector does the Unicycive Therapeutics company belong to?
The Unicycive Therapeutics sector is Healthcare.
Unicycive Therapeutics UNCY included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}